![Pfizer Xeljanz, Tofacitinib (Tofacitinib-Citrat), JAK-Hemmer, 11-mg- Tabletten, einmal täglich in Form von Tabletten mit anhaltender Freisetzung, Frankreich Stockfotografie - Alamy Pfizer Xeljanz, Tofacitinib (Tofacitinib-Citrat), JAK-Hemmer, 11-mg- Tabletten, einmal täglich in Form von Tabletten mit anhaltender Freisetzung, Frankreich Stockfotografie - Alamy](https://c8.alamy.com/compde/2fmcwhr/pfizer-xeljanz-tofacitinib-tofacitinib-citrat-jak-hemmer-11-mg-tabletten-einmal-taglich-in-form-von-tabletten-mit-anhaltender-freisetzung-frankreich-2fmcwhr.jpg)
Pfizer Xeljanz, Tofacitinib (Tofacitinib-Citrat), JAK-Hemmer, 11-mg- Tabletten, einmal täglich in Form von Tabletten mit anhaltender Freisetzung, Frankreich Stockfotografie - Alamy
![FDA: Xeljanz, Xeljanz XR (tofacitinib) related to increased risk of blood clots and death | Life | northcentralpa.com FDA: Xeljanz, Xeljanz XR (tofacitinib) related to increased risk of blood clots and death | Life | northcentralpa.com](https://bloximages.newyork1.vip.townnews.com/northcentralpa.com/content/tncms/assets/v3/editorial/0/3c/03cf7412-b209-11e9-a5b3-03f005b81ac6/5d3efba3f1fc6.image.png?resize=1200%2C628)
FDA: Xeljanz, Xeljanz XR (tofacitinib) related to increased risk of blood clots and death | Life | northcentralpa.com
![Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis | Business Wire Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis | Business Wire](https://mms.businesswire.com/media/20160224006053/en/511097/5/2486042_XELJANZ_XR_LOGO_cmyk_lock_up+%281%29.jpg)